Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma

Hepatology Research

Volumn 41, Issue 1, 2011, Pages 64-70

  Nishi, Masaaki ^a   Shimada, Mitsuo ^a   Utsunomiya, Tohru ^a   Morine, Yuji ^a   Imura, Satoru ^a   Ikemoto, Tetsuya ^a   Mori, Hiroki ^a   Hanaoka, Jun ^a   Bando, Yoshimi ^b  

^a Department of Surgery ^*  (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Intrahepatic cholangiocarcinoma; Ki 67 index; Prognosis; Recurrent pattern

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; DIHYDROPYRIMIDINE DEHYDROGENASE; KI 67 ANTIGEN; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LIVER LOBECTOMY; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE DISSECTION; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 78650756151     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00722.x     Document Type: Article

References (30)

1. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 1368-78.
2. Madariaga JR, Iwatsuki S, Todo S, Lee RG, Irish W, Starzl TE. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998; 227: 70-9.
3. Tajima Y, Kuroki T, Fukuda K, Tsuneoka N, Furui J, Kanematsu T. An intraductal papillary component is associated with prolonged survival after hepatic resection for intrahepatic cholangiocarcinoma. Br J Surg 2004; 91: 99-104.
4. Ikai I, Arii S, Okazaki M et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-91.
5. Shimada M, Sugimoto K, Iwahashi S et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 2010; 45: 896-902.
6. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5: 1947-9.
7. Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 15: 4116-24.
8. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
9. Yu Z, Sun J, Zhen J, Zhang Q, Yang Q. Thymidylate synthase predicts for clinical outcome in invasive breast cancer. Histol Histopathol 2005; 20: 871-8.
10. Obara S, Yamamoto K, Hosogai N, Yoshimura Y. Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma. Oral Oncol 2005; 41: 276-82.
11. Toi M, Ikeda T, Akiyama F et al. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy. Int J Oncol 2007; 31: 899-906.
12. Lassmann S, Hennig M, Rosenberg R et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors - correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 2006; 21: 238-47.
13. Fujiwaki R, Hata K, Nakayama K et al. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000; 18: 3946-51.
14. Takenoue T, Nagawa H, Matsuda K. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000; 7: 193-8.
15. Shintani Y, Ohta M, Hirabayashi H. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004; 45: 189-96.
16. Nii A, Shimada M, Ikegami T et al. Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma. Hepatol Res 2009; 39: 274-81.
17. Tepsiri N, Chaturat L, Sripa B et al. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol 2005; 11: 2748-53.
18. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Cancer, 2nd edn. Tokyo: Kanehara, 2003.
19. Takenoue T, Kitayama J, Takei Y et al. Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann Oncol 2000; 11: 273-9.
20. Yasumatsu R, Nakashima T, Uryu H et al. The role of dihydropyrimidine dehydrogenase expression in resistance to 5-fluorouracil in head and neck squamous cell carcinoma cells. Oral Oncol 2009; 45: 141-7.
21. Baba H, Teramoto K, Kawamura T, Mori A, Imamura M, Arii S. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol 2003; 52: 469-76.
22. Ikeguchi M, Hirooka Y, Makino M, Kaibara N. Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine. Oncol Rep 2001; 8: 621-5.
23. Shimoda M, Sawada T, Kubota K. Thymidylate synthase and dihydropyrimidine dehydrogenase are upregulated in pancreatic and biliary tract cancers. Pathobiology 2009; 76: 193-8.
24. Ajiki T, Hirata K, Okazaki T et al. Thymidylate synthase and dihydropyrimidine dehydrogenase expressions in gallbladder cancer. Anticancer Res 2006; 26: 1391-6.
25. Heidelberger C. Cancer chemotherapy with purine and pyrimidine analogues. Annu Rev Pharmacol 1967; 7: 101-24.
26. Johnston SJ, Ridge SA, Cassidy J, McLeod HL. Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 1999; 5: 2566-70.
27. Tuchman M, O'Dea RF, Ramnaraine ML, Mirkin BL. Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors. J Clin Invest 1988; 81: 425-30.
28. Christopher S, Williams CS, Tuchman M. Correlations of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidine kinase activities in strongly and weakly malignant cultured murine neuroblastoma cells. Int J Cancer 1989; 43: 901-4.
29. Ichikawa W, Takahashi T, Suto K et al. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in relation to differentiation of gastric cancer. Int J Cancer 2004; 112: 967-73.
30. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. Clin Cancer Res 1998; 4: 1227-34.